- Home
- INKT vs ACXP Comparison
INKT vs ACXP Comparison
Compare INKT & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INKT
- ACXP
- Stock Information
- Founded
- INKT 2017
- ACXP 2017
- Country
- INKT United States
- ACXP United States
- Employees
- INKT N/A
- ACXP N/A
- Industry
- INKT Medicinal Chemicals and Botanical Products
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- INKT Health Care
- ACXP Health Care
- Exchange
- INKT Nasdaq
- ACXP Nasdaq
- Market Cap
- INKT 28.9M
- ACXP 8.4M
- IPO Year
- INKT 2021
- ACXP 2021
- Fundamental
- Price
- INKT $7.04
- ACXP $0.49
- Analyst Decision
- INKT Strong Buy
- ACXP Strong Buy
- Analyst Count
- INKT 2
- ACXP 2
- Target Price
- INKT $37.50
- ACXP $10.00
- AVG Volume (30 Days)
- INKT 14.7K
- ACXP 18.6M
- Earning Date
- INKT 08-12-2025
- ACXP 08-08-2025
- Dividend Yield
- INKT N/A
- ACXP N/A
- EPS Growth
- INKT N/A
- ACXP N/A
- EPS
- INKT N/A
- ACXP N/A
- Revenue
- INKT N/A
- ACXP N/A
- Revenue This Year
- INKT N/A
- ACXP N/A
- Revenue Next Year
- INKT N/A
- ACXP N/A
- P/E Ratio
- INKT N/A
- ACXP N/A
- Revenue Growth
- INKT N/A
- ACXP N/A
- 52 Week Low
- INKT $4.56
- ACXP $0.30
- 52 Week High
- INKT $13.79
- ACXP $3.33
- Technical
- Relative Strength Index (RSI)
- INKT 47.56
- ACXP 51.01
- Support Level
- INKT $6.91
- ACXP $0.46
- Resistance Level
- INKT $7.51
- ACXP $0.56
- Average True Range (ATR)
- INKT 0.32
- ACXP 0.10
- MACD
- INKT -0.02
- ACXP -0.01
- Stochastic Oscillator
- INKT 27.28
- ACXP 24.27
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.